Recent Analysts’ Ratings Changes for Eyepoint Pharmaceuticals (EYPT)

Eyepoint Pharmaceuticals (NASDAQ: EYPT) has recently received a number of price target changes and ratings updates:

• 10/20/2026 – Eyepoint Pharmaceuticals was downgraded by Laidlaw from “buy” to “hold”.
• 10/20/2026 – Eyepoint Pharmaceuticals had its price target lowered by Royal Bank Of Canada to $1.00. They now have a “sector perform” rating on the stock.
• 10/20/2026 – Eyepoint Pharmaceuticals had its “neutral” rating reaffirmed by HC Wainwright.
• 10/20/2026 – Eyepoint Pharmaceuticals was downgraded by JPMorgan Chase & Co. from “neutral” to “underweight”.
• 10/20/2026 – Eyepoint Pharmaceuticals was downgraded by Mizuho from “outperform” to “neutral”. They now have a $0.50 price target on the stock.
• 10/19/2026 – Eyepoint Pharmaceuticals was downgraded by Guggenheim from “buy” to “neutral”.
• 10/19/2026 – Eyepoint Pharmaceuticals was downgraded by Jefferies Financial Group from “buy” to “hold”. They now have a $1.00 price target on the stock.
• 9/27/2026 – Eyepoint Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 9/19/2026 – Eyepoint Pharmaceuticals was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 9/2/2026 – Eyepoint Pharmaceuticals was downgraded by TD Cowen from “buy” to “hold”. They now have a $4.00 price target on the stock, down from $20.00.
• 9/1/2026 – Eyepoint Pharmaceuticals was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for serious eye diseases. The company specializes in sustained-release drug delivery for the retina and other parts of the eye, with the goal of reducing the frequency of injections and improving treatment convenience for patients.

EyePoint’s commercial products include YUTIQ, an injectable fluocinolone acetonide intravitreal implant used to treat chronic noninfectious posterior uveitis, and DEXYCU, an ophthalmic formulation of dexamethasone used to treat inflammation following ocular surgery.